← Browse by Condition
Medical Condition
primary mediastinal large b cell lymphoma refractory
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas — each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Trial Phases
Phase 1 2
Top Sponsors
1 trial
1 trial
NCT06209619 Phase 1
Recruiting
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Enrollment
18 pts
Location
United States
Sponsor
Nathan Denlinger
NCT06703892 Phase 1
Recruiting
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Enrollment
18 pts
Location
Taiwan
Sponsor
GenomeFrontier Therapeutics TW...
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology